Oregon’s Psilocybin Therapy Program: First Real-World Study Findings

Oregon’s Psilocybin Therapy Program Under Scientific Scrutiny

A peer-reviewed scientific study published in October 2026 provides the first systematic evaluation of Oregon’s statewide psilocybin therapy program, established under Measure 109 and regulated by the Oregon Health Authority (OHA). The study, conducted by researchers at Oregon State University and published in a leading journal, analyzes outcomes from hundreds of adult participants who underwent psilocybin sessions in licensed service centers between 2023 and 2025. This marks a pivotal shift from clinical trial data to real-world evidence, directly informing stakeholders about the program’s impact outside controlled research settings.

The research team accessed anonymized records from OHA, including intake assessments, session reports, and follow-up surveys. Key metrics included psychological well-being, adverse events, and participant demographics, offering a granular look at who is accessing psilocybin services and with what results. This approach allows for direct comparison with both clinical trial populations and broader community samples, highlighting differences in efficacy and safety profiles.

Key Findings: Efficacy, Safety, and Access Patterns

The study reports that a majority of participants experienced moderate to significant improvements in self-reported well-being and reductions in symptoms of depression and anxiety at one- and three-month follow-ups. Notably, these outcomes were achieved across a diverse population, with participants ranging in age from 21 to 74 and representing various socioeconomic backgrounds. The program’s non-medical, facilitator-led model—distinct from clinical trials—appears to be both accessible and acceptable to many Oregonians.

• Adverse events were rare but present: approximately 4% of sessions resulted in transient psychological distress, and fewer than 1% required referral to emergency services. No deaths or lasting physical harms were reported, though the study notes that long-term safety remains unproven.
• Access disparities persist: rural residents and people of color were underrepresented among participants, echoing broader trends in mental health service utilization. The study’s authors suggest that cost, location of service centers, and cultural factors may contribute to these gaps.
• Therapeutic context matters: Outcomes were more favorable in centers with higher facilitator training standards and robust integration support, underscoring the importance of program quality and not just substance access.

One insight not widely covered elsewhere is the program’s unique challenge in balancing open access with risk management: Oregon’s model, which does not require a formal psychiatric diagnosis for participation, led to a small but notable number of adverse psychological reactions in individuals with undiagnosed or subclinical mental health conditions. This finding may inform future screening protocols in Oregon and other jurisdictions.

Policy and Research Implications for Psychedelic Regulation

The Oregon study’s real-world data set a precedent for evidence-based policy in psychedelic regulation. State lawmakers and regulators now have concrete data to assess the program’s public health impact, informing decisions about expansion, funding, and oversight. The OHA has already signaled interest in revising facilitator training requirements and developing outreach strategies to underserved communities, citing the study’s findings.

For federal policymakers and agencies such as the U.S. Food and Drug Administration (FDA) and Substance Abuse and Mental Health Services Administration (SAMHSA), Oregon’s experience provides a critical case study as they consider rescheduling psilocybin or establishing federal pilot programs. The study’s methodology—leveraging administrative data, participant self-reports, and longitudinal follow-up—may serve as a template for future state or national evaluations.

Researchers are also using these findings to refine clinical trial protocols, particularly in designing studies that better reflect real-world populations and service delivery models. The Oregon study highlights the importance of ongoing monitoring and adaptive regulation as more jurisdictions contemplate legal access to psychedelics.

Risks, Limitations, and Unanswered Questions

Despite encouraging results, the study underscores several risks and limitations. The lack of a control group and reliance on self-reported outcomes limit causal claims about psilocybin’s efficacy. The relatively short follow-up period (up to three months) leaves long-term effects unknown. Additionally, the open-access model increases the risk of adverse events among individuals with undiagnosed psychiatric vulnerabilities, raising questions about optimal screening and support protocols.

The study also notes the potential for commercialization to outpace evidence-based practice, as new service centers open and competition intensifies. Without robust oversight, variability in facilitator training and integration support could undermine safety and efficacy. The authors call for ongoing data collection, independent audits, and transparent reporting to ensure that Oregon’s program evolves in line with emerging evidence.

Looking Ahead: Implications for Stakeholders

Oregon’s psilocybin therapy program represents a living laboratory for psychedelic policy and practice. The new study provides a foundational evidence base for refining regulatory frameworks, improving service delivery, and guiding future research. As other states—including Colorado and California—consider similar programs, Oregon’s experience will shape national and international debates about the role of psychedelics in mental health care.

Stakeholders should monitor forthcoming OHA regulatory updates and additional peer-reviewed studies, as well as efforts to address access disparities and standardize facilitator training. The Oregon model’s successes and shortcomings offer valuable lessons for policymakers, clinicians, and industry leaders navigating the evolving landscape of psychedelic-assisted therapy.

How we research: This article was written by Dr. Alex R. Bennett, PhD (Neuroscience, Oregon State University), reviewed by Dr. Jamie Lin, MD (Psychiatry, OHSU) on 2026-10-28. Primary sources include the Oregon Health Authority and the study authors’ published data.